Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Prognostic Score

Purpose: To evaluate a patient with newly diagnosed, cytogenetically normal acute myeloid leukemia (CN-AML) using the score of Malagola et al.

Info MyLikes MyPaths

Evaluation

Are you evaluating a patient with newly diagnosed, cytogenetically normal AML?

Yes

Age of the patient

years

White blood cell count

Is the AML primary?

Yes

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Total prognostic index score

Risk group

Estimated 5-year overall survival

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
- Prognostic Index of Breems et al (European Prognostic Score) for an Adult Patient with Acute Myelogenous Leukemia (AML) in the First Relapse
- Prognostic Score of Haferlach et al for Acute Myeloid Leukemia (AML)
Laboratory Tests
- Acute Myeloid Leukemia | Activity of Renin-Angiotensin System (RAS)
Severity, Prognosis, Stage
- Prognostic Index of Breems et al (European Prognostic Score) for an Adult Patient with Acute Myelogenous Leukemia (AML) in the First Relapse
- Prognostic Score of Haferlach et al for Acute Myeloid Leukemia (AML)
Complications
- Prognostic Index of Breems et al (European Prognostic Score) for an Adult Patient with Acute Myelogenous Leukemia (AML) in the First Relapse
- Prognostic Score of Haferlach et al for Acute Myeloid Leukemia (AML)

Therapy

Selection
- Prognostic Index of Breems et al (European Prognostic Score) for an Adult Patient with Acute Myelogenous Leukemia (AML) in the First Relapse
- Prognostic Score of Haferlach et al for Acute Myeloid Leukemia (AML)

Specialty

Hematology Oncology

Objective

risk factors
severity
prognosis
stage
selection

ICD-10

C92.0 - Acute myeloblastic leukaemia [AML]

Info

Purpose: To evaluate a patient with newly diagnosed, cytogenetically normal acute myeloid leukemia (CN-AML) using the score of Malagola et al.

Specialty: Hematology Oncology

Objective: risk factors, severity, prognosis, stage, selection

ICD-10: C92.0,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path